Independence Bank of Kentucky Reduces Holdings in Johnson & Johnson $JNJ

Independence Bank of Kentucky decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,773 shares of the company’s stock after selling 2,600 shares during the period. Johnson & Johnson makes up about 1.2% of Independence Bank of Kentucky’s investment portfolio, making the stock its 15th largest position. Independence Bank of Kentucky’s holdings in Johnson & Johnson were worth $9,722,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in JNJ. Blueline Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $25,000. Cresta Advisors Ltd. bought a new stake in Johnson & Johnson in the fourth quarter worth about $26,000. DecisionPoint Financial LLC grew its stake in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after buying an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC grew its stake in shares of Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after buying an additional 49 shares during the last quarter. Finally, Family CFO Inc purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $31,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target on Johnson & Johnson to $263 from $254, signaling continued support for the stock even as the firm kept a neutral rating. Benzinga report on the price target increase
• Positive Sentiment: Johnson & Johnson backed a new heart failure device trial, keeping investor focus on its medtech pipeline and longer-term growth opportunities in electrophysiology and cardiovascular care. JNJ Backs New Heart Failure Device Trial
• Positive Sentiment: Analysts continued to highlight JNJ as a strong dividend and defensive healthcare name, with several notes pointing to the company’s earnings consistency and attractive income profile. TipRanks dividend aristocrat article
• Neutral Sentiment: Investors are also looking ahead to J&J’s upcoming Q2 earnings report, with previews suggesting the company may again beat expectations, but the market is still waiting for actual results. Zacks Q2 earnings preview
• Negative Sentiment: An Illinois appellate court affirmed a $45 million mesothelioma verdict against Johnson & Johnson and Kenvue tied to talc-related asbestos allegations, renewing legal risk concerns that can weigh on the shares. Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. Morgan Stanley boosted their price objective on Johnson & Johnson from $283.00 to $284.00 and gave the company an “overweight” rating in a report on Wednesday. Bank of America increased their target price on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research note on Friday. Argus boosted their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Thursday, April 16th. Citigroup upped their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Johnson Rice set a $270.00 price objective on shares of Johnson & Johnson in a report on Friday, June 26th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $258.13.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $257.17 on Monday. Johnson & Johnson has a twelve month low of $154.80 and a twelve month high of $269.43. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a fifty day simple moving average of $237.07 and a two-hundred day simple moving average of $233.23. The stock has a market capitalization of $619.07 billion, a price-to-earnings ratio of 29.73, a P/E/G ratio of 2.51 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same quarter last year, the firm posted $2.77 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts predict that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, May 26th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.